Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium announced promising interim data from the EQUALISE study on itolizumab for systemic lupus erythematosus (SLE). Notably, patients showed a reduction of 42% in proteinuria and 54% in albuminuria after treatment. The study involved 35 SLE patients and confirmed that itolizumab was well tolerated at doses from 0.4 to 2.4 mg/kg. Findings suggest it could be effective in treating SLE and related complications, with further data expected from ongoing research.
Equillium, Inc. (Nasdaq: EQ) has announced the acceptance of two abstracts for presentation at the virtual 2021 American Society of Nephrology Annual Meeting, taking place from November 4-7, 2021. The abstracts focus on itolizumab, a novel anti-CD6 antibody, and highlight its safety and efficacy in treating systemic lupus erythematosus (SLE). The EQUALISE study evaluates itolizumab's effects on patients with SLE and lupus nephritis. Itolizumab is designed to modulate immune responses in severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ) has announced that three abstracts will be presented at the ACR Convergence from November 3-10, highlighting the use of itolizumab for treating systemic lupus erythematosus (SLE) and lupus nephritis. The abstracts report on safety results from the Phase 1b EQUALISE study, pharmacodynamic markers, and the potential role of urinary ALCAM as a biomarker for renal disease activity. Itolizumab is a first-in-class monoclonal antibody targeting the CD6-ALCAM pathway, aimed at managing severe autoimmune disorders.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology firm, will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27 to 30, 2021. On September 29 at 10:40 AM ET, CEO Bruce Steel and CMO Dolca Thomas will discuss itolizumab's mechanism and ongoing clinical programs, particularly its Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD).
A live webcast will be available at Equillium's website, with an archived replay for 90 days.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The virtual presentation, available starting September 13 at 7:00 am ET, will cover itolizumab's mechanism of action and ongoing clinical programs. Key highlights include topline data from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) and upcoming pivotal Phase 3 study. The webcast will be accessible for 90 days on their website.
Equillium, Inc. (Nasdaq: EQ) announced promising exploratory data from the EQUALISE study involving itolizumab for treating systemic lupus erythematosus (SLE). Patients without lupus nephritis but with elevated urine protein experienced significant reductions in UPCR, with a 33% and 42% decrease noted at Days 29 and 57, respectively. Additionally, patients with elevated albumin/creatinine ratios showed similar improvements. The company plans to amend the study to include newly diagnosed lupus nephritis patients and expects interim results by year-end, bolstered by FDA fast track designation for itolizumab.
Equillium (Nasdaq: EQ) reported positive financial and clinical developments for Q2 2021. Notably, positive results from the Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) were highlighted, prompting plans to advance to a pivotal Phase 3 study. R&D expenses rose to $6.0 million from $3.9 million year-over-year, while net loss widened to $9.2 million, or $(0.31) per share, compared to $(0.37) per share last year. Cash reserves were $97.6 million, expected to fund operations into 2023.
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, announced its participation in the BTIG Virtual Biotechnology Conference on August 9 & 10, 2021. CEO Bruce Steel and Dr. Dolca Thomas, EVP of R&D and CMO, will present a clinical overview and engage in a Fireside Chat with analyst Justin Zelin. The event is set for August 10, 2021, at 12 PM ET via a virtual webcast. Equillium is focused on developing itolizumab to address severe autoimmune and inflammatory disorders, including aGVHD, lupus, and asthma.
Equillium, Inc. (Nasdaq: EQ) has successfully completed an End-of-Phase 1 meeting with the FDA for itolizumab, targeting first-line treatment for acute graft-versus-host disease (aGVHD). This outcome paves the way for a pivotal Phase 3 study aimed at supporting a Biologics License Application (BLA). The study is set to begin in Q4 2021 and will compare itolizumab to standard high-dose corticosteroids, with complete response at Day 29 as the primary endpoint. Itolizumab has received FDA fast track and orphan drug designations.
Equillium, Inc. has announced promising topline results from the Phase 1b EQUATE study for its drug, itolizumab, targeting first-line acute graft-versus-host disease (aGVHD). In a cohort of 20 high-risk patients, the study reported a 55% complete response rate and a 70% overall response rate by Day 29. Patients experienced rapid, durable responses, leading to a significant 67% reduction in corticosteroid usage. The FDA has granted itolizumab fast track and orphan drug designations for aGVHD, with plans for pivotal studies ahead.
